FDA Accepts Clovis Oncology ’s NDA for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer

BOULDER, Colo.--(BUSINESS WIRE)--Aug. 23, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Clovis ’ New Drug Application (NDA) for accelerated approval of rucaparib and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news